Literature DB >> 11157473

Nucleotide receptors: an emerging family of regulatory molecules in blood cells.

F Di Virgilio1, P Chiozzi, D Ferrari, S Falzoni, J M Sanz, A Morelli, M Torboli, G Bolognesi, O R Baricordi.   

Abstract

Nucleotides are emerging as an ubiquitous family of extracellular signaling molecules. It has been known for many years that adenosine diphosphate is a potent platelet aggregating factor, but it is now clear that virtually every circulating cell is responsive to nucleotides. Effects as different as proliferation or differentiation, chemotaxis, release of cytokines or lysosomal constituents, and generation of reactive oxygen or nitrogen species are elicited upon stimulation of blood cells with extracellular adenosine triphosphate (ATP). These effects are mediated through a specific class of plasma membrane receptors called purinergic P2 receptors that, according to the molecular structure, are further subdivided into 2 subfamilies: P2Y and P2X. ATP and possibly other nucleotides are released from damaged cells or secreted via nonlytic mechanisms. Thus, during inflammation or vascular damage, nucleotides may provide an important mechanism involved in the activation of leukocytes and platelets. However, the cell physiology of these receptors is still at its dawn, and the precise function of the multiple P2X and P2Y receptor subtypes remains to be understood.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157473     DOI: 10.1182/blood.v97.3.587

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  222 in total

1.  Cytokine regulation of gap junction connectivity: an open-and-shut case or changing partners at the Nexus?

Authors:  C F Brosnan; E Scemes; D C Spray
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

2.  Extracellular purines from cells of seminiferous tubules.

Authors:  Daniel Pens Gelain; Luiz Fernando de Souza; Elena Aida Bernard
Journal:  Mol Cell Biochem       Date:  2003-03       Impact factor: 3.396

Review 3.  A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases.

Authors:  Nishkantha Arulkumaran; Robert J Unwin; Frederick Wk Tam
Journal:  Expert Opin Investig Drugs       Date:  2011-04-21       Impact factor: 6.206

4.  Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes.

Authors:  Cristina Andrei; Paola Margiocco; Alessandro Poggi; Lavinia V Lotti; M R Torrisi; Anna Rubartelli
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-10       Impact factor: 11.205

5.  ATP-P2X7 receptor signaling controls basal and TNFα-stimulated glial cell proliferation.

Authors:  Jian Zou; Ryan P Vetreno; Fulton T Crews
Journal:  Glia       Date:  2012-02-01       Impact factor: 7.452

Review 6.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

7.  Both sides now: multiple interactions of ATP with pannexin-1 hemichannels. Focus on "A permeant regulating its permeation pore: inhibition of pannexin 1 channels by ATP".

Authors:  George R Dubyak
Journal:  Am J Physiol Cell Physiol       Date:  2009-02       Impact factor: 4.249

8.  The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway.

Authors:  Stefania Gardella; Cristina Andrei; Denise Ferrera; Lavinia V Lotti; Maria R Torrisi; Marco E Bianchi; Anna Rubartelli
Journal:  EMBO Rep       Date:  2002-09-13       Impact factor: 8.807

9.  Characterisation of the R276A gain-of-function mutation in the ectodomain of murine P2X7.

Authors:  Sahil Adriouch; Felix Scheuplein; Robert Bähring; Michel Seman; Olivier Boyer; Friedrich Koch-Nolte; Friedrich Haag
Journal:  Purinergic Signal       Date:  2009-02-21       Impact factor: 3.765

10.  P2X4, P2Y1 and P2Y2 receptors on rat alveolar macrophages.

Authors:  Jonathan W Bowler; R Jayne Bailey; R Alan North; Annmarie Surprenant
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.